|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|
| Net loss | ||
| Operating activities from continuing operations | ||
| Net (loss) income | ||
| Adjustments to reconcile net (loss) income from continuing operations to net cash provided by operating activities from continuing operations: | ||
| Depreciation and amortization | ||
| Loss on impairment | ||
| Equity-based compensation | ||
| Customer equity appreciation rights | ||
| Remeasurement of customer equity appreciation rights | ||
| Amortization of deferred financing fees | ||
| Amortization of right-of-use assets | ||
| Loss on extinguishment of debt | ||
| Remeasurement of contingent consideration | ||
| Payment of contingent consideration | ||
| Gain on sale of assets | ||
| Deferred income taxes | ||
| Tax Receivable Agreement liability adjustment | ||
| Other | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable | ||
| Prepaid expenses and other current assets | ||
| Contract assets | ||
| Other assets | ||
| Accounts payable and accrued expenses | ||
| Contract liabilities | ||
| Other current liabilities | ||
| Noncurrent operating lease liabilities | ||
| Other noncurrent liabilities | ||
| Net cash provided by operating activities | ||
| Net cash provided by operating activities from continuing operations | ||
| Investing activities from continuing operations | ||
| Capital expenditures - property and equipment | ||
| Capital expenditures - internal-use software development | ||
| Proceeds from sale of assets | ||
| Purchase of long-term investment | ||
| Business combinations, net of cash acquired | ||
| Cash acquired from Remedy Partners Acquisition | ||
| Net cash (used in) provided by investing activities | ||
| Net cash used in investing activities from continuing operations | ||
| Financing activities from continuing operations | ||
| Repayment of long-term debt | ||
| Proceeds from issuance of long-term debt | ||
| Repayment of borrowings under revolving credit facility | ||
| Proceeds from borrowings under revolving credit facility | ||
| Repayments of borrowings under financing agreement | ||
| Proceeds from borrowings under financing agreement | ||
| Payment of contingent consideration | ||
| Payment of debt issuance costs | ||
| Payment to sellers of Remedy | ||
| Distributions to/on behalf of non-controlling interest members | ||
| Proceeds from IPO, net | ||
| Refunds (payments) of taxes on behalf of New Remedy Corp | ||
| Repurchase of member units | ||
| Contributions from members | ||
| Proceeds related to the issuance of common stock under stock plans | ||
| Net cash provided by (used in) financing activities | ||
| Net cash provided by financing activities from continuing operations | ||
| Discontinued operations: | ||
| Total (used in) provided by operating activities | ||
| Total used in investing activities | ||
| Total used in financing activities | ||
| (Decrease) increase in cash, cash equivalents and restricted cash from discontinued operations | ||
| (Decrease) increase in cash, cash equivalents and restricted cash | ||
| Cash, cash equivalents and restricted cash - beginning of period | ||
| Cash, cash equivalents and restricted cash discontinued operations - beginning of period | ||
| Cash, cash equivalents and restricted cash - end of period | ||
| Less: Cash, cash equivalents and restricted cash discontinued operations - end of period | ||
| Cash, cash equivalents and restricted cash continuing operations- end of period | ||
| Supplemental disclosures of cash flow information | ||
| Cash paid for interest | ||
| Cash payments, net of refunds, for taxes | ||
| Noncash transactions | ||
| Capital expenditures not yet paid | ||
| Assumption of liabilities from New Remedy Corp | ||
| Issuance of common stock related to acquisition | ||
| Items arising from LLC interest ownership exchanges: | ||
| Establishment of liabilities under tax receivable agreement | ||
| Deferred tax asset |
Loading...
